Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta A Renzoni

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Respirology (Carlton, Vic.)|October 20, 2025
Conspiracy Theories, MDTs and CommunicationElisabetta A Renzoni
American Journal of Respiratory and Critical Care Medicine|May 27, 2004
Neovascularization in idiopathic pulmonary fibrosis: too much or too little?Elisabetta A Renzoni
Respirology (Carlton, Vic.)|May 17, 2019
Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny pathElisabetta A Renzoni, Athol U Wells
International Journal of Rheumatology|September 19, 2012
Circulating biomarkers of interstitial lung disease in systemic sclerosisHarpreet K Lota, Elisabetta A Renzoni
Molecular Diagnosis & Therapy|June 18, 2014
Molecular biomarkers in interstitial lung diseasesAngelo De Lauretis, Elisabetta A Renzoni
American Journal of Respiratory Cell and Molecular Biology|May 8, 2010
Endothelin in pulmonary fibrosisCarmen Fonseca, David Abraham, Elisabetta A Renzoni
Rheumatology (Oxford, England)|February 10, 2024
Comment on: Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease: ReplyJennifer Hannah, Elisabetta A Renzoni, Patrick Gordon
Current Opinion in Immunology|October 14, 2025
Treating sarcoidosis: when less is moreNiamh Logan, Jessica Raja, Elisabetta A Renzoni
European Journal of Human Genetics : EJHG|February 25, 2018
Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literatureCarmel J W Stock, Elisabetta A Renzoni
Journal of Clinical Medicine|April 3, 2021
Telomeres in Interstitial Lung DiseaseCarmel J W Stock, Elisabetta A Renzoni
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Respirology (Carlton, Vic.)|October 20, 2025
Conspiracy Theories, MDTs and CommunicationElisabetta A Renzoni
American Journal of Respiratory and Critical Care Medicine|May 27, 2004
Neovascularization in idiopathic pulmonary fibrosis: too much or too little?Elisabetta A Renzoni
Respirology (Carlton, Vic.)|May 17, 2019
Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny pathElisabetta A Renzoni, Athol U Wells
International Journal of Rheumatology|September 19, 2012
Circulating biomarkers of interstitial lung disease in systemic sclerosisHarpreet K Lota, Elisabetta A Renzoni
Molecular Diagnosis & Therapy|June 18, 2014
Molecular biomarkers in interstitial lung diseasesAngelo De Lauretis, Elisabetta A Renzoni
American Journal of Respiratory Cell and Molecular Biology|May 8, 2010
Endothelin in pulmonary fibrosisCarmen Fonseca, David Abraham, Elisabetta A Renzoni
Rheumatology (Oxford, England)|February 10, 2024
Comment on: Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease: ReplyJennifer Hannah, Elisabetta A Renzoni, Patrick Gordon
Current Opinion in Immunology|October 14, 2025
Treating sarcoidosis: when less is moreNiamh Logan, Jessica Raja, Elisabetta A Renzoni
European Journal of Human Genetics : EJHG|February 25, 2018
Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literatureCarmel J W Stock, Elisabetta A Renzoni
Journal of Clinical Medicine|April 3, 2021
Telomeres in Interstitial Lung DiseaseCarmel J W Stock, Elisabetta A Renzoni
Pageof 14